254 In Vitro and in Vivo Antitumor Activity of the Investigational Aurora A Selective Kinase Inhibitor MLN8237 Alone and in Combination with Standard Agents Against CRC Models von Pitts, T.M, McPhillips, K.L, Selby, H.M, Spreafico, A, Bagby, S.M, Britt, B.C, Tan, A.C, Tentler, J.J, Ecsedy, J.A, Eckhardt, S.G

Volltext

Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion von Do, T-V, Xiao, F, Bickel, L E, Klein-Szanto, A J, Pathak, H B, Hua, X, Howe, C, O'Brien, S W, Maglaty, M, Ecsedy, J A, Litwin, S, Golemis, E A, Schilder, R J, Godwin, A K, Connolly, D C

Volltext

75 The Aurora A kinase inhibitor MLN8237 in combination with docetaxel induces synergistic antitumor activity in triple-negative breast cancer xenograft models von Zhang, M, Huck, J.J, Hyer, M.L, Kannan, K, Stroud, S, Ecsedy, J.A, Manfredi, M.G

Volltext

289 POSTER Aurora A kinase inhibition abrogates the mitotic delay induced by microtubule perturbing agents von Wysong, D.R, Chakravarty, A, Hoar, K, Ecsedy, J.A

Volltext

280 POSTER Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MLN8237, a selective Aurora A kinase inhibitor, in the United States von Infante, J, Dees, E.C, Cohen, R.B, Burris, H, O'Neil, B, Murphy, P, Lee, Y, Pappas, J, Ecsedy, J.A, Eton, O

Volltext